Emerging engineered magnetic nanoparticulate probes for molecular MRI of atherosclerosis: How far have we come?

Nanomedicine

Volumn 7, Issue 6, 2012, Pages 899-916

  Kanwar, Rupinder K ^a   Chaudhary, Rajneesh ^a   Tsuzuki, Takuya ^a   Kanwar, Jagat R ^a  

^a DEAKIN UNIVERSITY   (Australia)

Author keywords

angiogenesis; atherosclerosis; cell adhesion molecules; gadolinium; heat shock proteins; iron oxide nanoparticles; MRI; platelets

Indexed keywords

CELL ADHESION MOLECULE; CHEMOKINE; CONTRAST MEDIUM; CYTOKINE; ELASTIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GADOLINIUM; HEAT SHOCK PROTEIN; MAGNETIC NANOPARTICLE; OXIDIZED LOW DENSITY LIPOPROTEIN; PADGEM PROTEIN; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE;

APOPTOSIS; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; ATHEROSCLEROTIC PLAQUE; BIOMEDICAL ENGINEERING; BLOOD FLOW; CARDIOVASCULAR MAGNETIC RESONANCE; CELL DIFFERENTIATION; DIAGNOSTIC ACCURACY; DISEASE COURSE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; FOAM CELL; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; LEUKOCYTE MIGRATION; MACROPHAGE; NON INVASIVE MEASUREMENT; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REPRODUCIBILITY; REVIEW; SMOOTH MUSCLE FIBER; STROKE; THROMBOSIS; UPREGULATION;

ANIMALS; ARTERIES; ATHEROSCLEROSIS; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES; PLAQUE, ATHEROSCLEROTIC;

EID: 84862839443     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.12.57     Document Type: Review

References (94)

1. Kanwar RK, Kanwar JR, Wang D, Ormrod DJ, Krissansen GW. Temporal expression of heat shock proteins 60 and 70 at lesion-prone sites during atherogenesis in apoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 21(12), 1991-1997 (2001).
2. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352(16), 1685-1695 (2005).
3. Naghavi M, Libby P, Falk E et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation 108(14), 1664-1672 (2003).
4. Burke AP, Farb A, Malcom GT, Liang YH, Smialek J, Virmani R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N. Engl. J. Med. 336(18), 1276-1282 (1997).
5. Murray CJL, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 349(9064), 1498-1504 (1997).
6. Libby P, Aikawa M. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat. Med. 8(11), 1257-1262 (2002).
7. Lamon BD, Hajjar DP. Inflammation at the molecular interface of atherogenesis: an anthropological journey. Am. J. Pathol. 173(5), 1253-1264 (2008).
8. Glass CK, Witztum JL. Atherosclerosis. The road ahead. Cell 104(4), 503-516 (2001).
9. Osborn EA, Jaffer FA. The year in molecular imaging. JACC Cardiovasc. Imaging 3(11), 1181-1195 (2010).
10. Kanwar RK, Chaudhary R, Tsuzuki T, Kanwar JR. Emerging engineered magnetic nanoparticulate probes for targeted magnetic resonance imaging of atherosclerotic plaque macrophages. Nanomedicine Lond.) 7(5), 735-749 (2012).
11. Gimbrone MA, Topper JN, Nagel T, Anderson KR, Garcia-Cardeña G. Endothelial dysfunction, hemodynamic forces, and atherogenesisa. Ann. NY Acad. Sci. 902(1), 230-240 (2000).
12. Douglas G, Channon KM. The pathogenesis of atherosclerosis. Medicine 38(8), 397-402 (2010).
13. Andrew CN. An overview of the vascular response to injury: a tribute to the late Russell Ross. Toxicol. Lett. 112-113(0), 519-529 (2000).
14. Lusis AJ. Atherosclerosis. Nature 407(6801), 233-241 (2000).
15. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 104(3), 365-372 (2001).
16. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler. Thromb. Vasc. Biol. 23(2), 168-175 (2003).
17. Diodati JG, Dakak N, Gilligan DM, Quyyumi AA. Effect of atherosclerosis on endothelium-dependent inhibition of platelet activation in humans. Circulation 98(1), 17-24 (1998).
18. Anderson TJ. Assessment and treatment of endothelial dysfunction in humans. J. Am. Coll. Cardiol. 34(3), 631-638 (1999).
19. Kanwar JR, Kanwar RK, Burrow H, Baratchi S. Recent advances on the roles of NO in cancer and chronic inflammatory disorders. Curr. Med. Chem. 16(19), 2373-2394 (2009).
20. De Caterina R, Libby P, Peng HB et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J. Clin. Invest. 96(1), 60-68 (1995).
21. Erling F. Pathogenesis of atherosclerosis. J. Am. Coll. Cardiol. 47(Suppl. 8), C7-C12 (2006).
22. Tabas I, Williams KJ, Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 116(16), 1832-1844 (2007).
23. Xu Q. Role of heat shock proteins in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 22(10), 1547-1559 (2002).
24. Morimoto RI, Kline MP, Bimston DN, Cotto JJ. The heat-shock response: regulation and function of heat-shock proteins and molecular chaperones. Essays Biochem. 32, 17-29 (1997).
25. Kleindienst R, Xu Q, Willeit J, Waldenberger FR, Weimann S, Wick G. Immunology of atherosclerosis. Demonstration of heat shock protein 60 expression and T lymphocytes bearing alpha/beta or gamma/delta receptor in human atherosclerotic lesions. Am. J. Pathol. 142(6), 1927-1937 (1993).
26. Bielecka-Dabrowa A, Barylski M, Mikhailidis DP, Rysz J, Banach M. HSP 70 and atherosclerosis - protector or activator? Expert Opin. Ther. Targets 13(3), 307-317 (2009).
27. Schett G, Xu Q, Amberger A et al. Autoantibodies against heat shock protein 60 mediate endothelial cytotoxicity. J. Clin. Invest. 96(6), 2569-2577 (1995).
28. Pockley AG, Wu R, Lemne C, Kiessling R, De Faire U, Frostegard J. Circulating heat shock protein 60 is associated with early cardiovascular disease. Hypertension 36(2), 303-307 (2000).
29. Halcox JP, DeanfJ, Shamaei-Tousi A et al. Circulating human heat shock protein 60 in the blood of healthy teenagers: a novel determinant of endothelial dysfunction and early vascular injury? Arterioscler. Thromb. Vasc. Biol. 25(11), e141-142 (2005).
30. Herz I, Rosso R, Roth A, Keren G, George J. Serum levels of anti-heat shock protein 70 antibodies in patients with stable and unstable angina pectoris. Acute Card. Care 8(1), 46-50 (2006).
31. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat. Rev. Immunol. 6(7), 508-519 (2006).
32. Mandal K, Jahangiri M, Xu Q. Autoimmunity to heat shock proteins in atherosclerosis. Autoimmun. Rev. 3(2), 31-37 (2004).
33. Afek A, George J, Gilburd B et al. Immunization of low-density lipoprotein receptor deficient (LDL-RD) mice with heat shock protein 65 (HSP-65) promotes early atherosclerosis. J. Autoimmun. 14(2), 115-121 (2000).
34. Rigano R, Profumo E, Buttari B et al. Heat shock proteins and autoimmunity in patients with carotid atherosclerosis. Ann. NY Acad. Sci. 1107, 1-10 (2007).
35. Langille B, O'Donnell F. Reductions in arterial diameter produced by chronic decreases in blood flow are endothelium-dependent. Science 231(4736), 405-407 (1986).
36. Joris I, Zand T, Majno G. Hydrodynamic injury of the endothelium in acute aortic stenosis. Am. J. Pathol. 106(3), 394-408 (1982).
37. Walpola PL, Gotlieb AI, Cybulsky MI, Langille BL. Expression of ICAM1 and VCAM1 and monocyte adherence in arteries exposed to altered shear stress. Arterioscler. Thromb. Vasc. Biol. 15(1), 2-10 (1995).
38. Zand T, Hoffman AH, Savilonis BJ et al. Lipid deposition in rat aortas with intraluminal hemispherical plug stenosis: a morphological and biophysical study. Am. J. Pathol. 155(1), 85-92 (1999).
39. Vallance P, Chan N. Endothelial function and nitric oxide: clinical relevance. Heart 85(3), 342-350 (2001).
40. Chatzizisis YS, Coskun AU, Jonas M, Edelman ER, Feldman CL, Stone PH. Role of endothelial shear stress in the natural history of coronary atherosclerosis and vascular remodeling: molecular, cellular, and vascular behavior. J. Am. Coll. Cardiol. 49(25), 2379-2393 (2007).
41. Borén J, Olin K, Lee I, Chait A, Wight TN, Innerarity TL. Identification of the principal proteoglycan-binding site in LDL. A single-point mutation in apo-B100 severely affects proteoglycan interaction without affecting LDL receptor binding. J. Clin. Invest. 101(12), 2658-2664 (1998).
42. Knowles JW, Reddick RL, Jennette JC, Shesely EG, Smithies O, Maeda N. Enhanced atherosclerosis and kidney dysfunction in eNOS(-/-) apoE(-/-) mice are ameliorated by enalapril treatment. J. Clin. Invest. 105(4), 451-458 (2000).
43. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat. Immunol. 12(3), 204-212 (2011).
44. Auffray C, Fogg D, Garfa M et al. Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science 317(5838), 666-670 (2007).
45. Kol A, Bourcier T, Lichtman AH, Libby P. Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages. J. Clin. Invest. 103(4), 571-577 (1999).
46. Ellins E, Shamaei-Tousi A, Steptoe A et al. The relationship between carotid stiffness and circulating levels of heat shock protein 60 in middle-aged men and women. J. Hypertens. 26(12), 2389-2392 (2008).
47. Zernecke A, Shagdarsuren E, Weber C. Chemokines in atherosclerosis: an update. Arterioscler. Thromb. Vasc. Biol. 28(11), 1897-1908 (2008).
48. Boring L, Gosling J, Cleary M, Charo IF. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394(6696), 894-897 (1998).
49. Gu L, Okada Y, Clinton SK et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol. Cell. 2(2), 275-281 (1998).
50. Watanabe T, Fan J. Atherosclerosis and inflammation mononuclear cell recruitment and adhesion molecules with reference to the implication of ICAM1/LFA-1 pathway in atherogenesis. Int. J. Cardiol. 66(Suppl. 1), S45-S53; discussion S55 (1998).
51. Blankenberg S, Barbaux S, Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis 170(2), 191-203 (2003).
52. Zernecke A, Liehn EA, Fraemohs L et al. Importance of junctional adhesion molecule-A for neointimal lesion formation and infiltration in atherosclerosis-prone mice. Arterioscler. Thromb. Vasc. Biol. 26(2), e10-e13 (2006).
53. McLaren JE, Michael DR, Ashlin TG, Ramji DP. Cytokines, macrophage lipid metabolism and foam cells: implications for cardiovascular disease therapy. Prog. Lipid Res. 50(4), 331-347 (2011).
54. Nakashima Y, Raines EW, Plump AS, Breslow JL, Ross R. Upregulation of VCAM1 and ICAM1 at atherosclerosis-prone sites on the endothelium in the ApoE-deficient mouse. Arterioscler. Thromb. Vasc. Biol. 18(5), 842-851 (1998).
55. Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol. Rev. 58(3), 342-374 (2006).
56. Tabas I. Macrophage death and defective infresolution in atherosclerosis. Nat. Rev. Immunol. 10(1), 36-46 (2010).
57. Packard RR, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin. Chem. 54(1), 24-38 (2008).
58. Rudijanto A. The role of vascular smooth muscle cells on the pathogenesis of atherosclerosis. Acta Med. Indones. 39(2), 86-93 (2007).
59. Mallat Z, Taleb S, Ait-Oufella H, Tedgui A. The role of adaptive T cell immunity in atherosclerosis. J. Lipid Res. 50(Suppl.), S364-S369 (2009).
60. Moreno PR, Purushothaman K-R, Sirol M, Levy AP, Fuster V. Neovascularization in human atherosclerosis. Circulation 113(18), 2245-2252 (2006).
61. De Boer OJ, Van Der Wal AC, Teeling P, Becker AE. Leucocyte recruitment in rupture prone regions of lipid-rich plaques: a prominent role for neovascularization? Cardiovasc. Res. 41(2), 443-449 (1999).
62. Ehara S, Kobayashi Y, Yoshiyama M et al. Spotty calcification typifies the culprit plaque in patients with acute myocardial infarction. Circulation 110(22), 3424-3429 (2004).
63. Tedgui A, Mallat Z. Apoptosis as a determinant of atherothrombosis. Thromb. Haemost. 86(1), 420-426 (2001).
64. Schaar JA, Muller JE, Falk E et al. Terminology for high-risk and vulnerable coronary artery plaques. Eur. Heart J. 25(12), 1077-1082 (2004).
65. Sukhova GK, Schonbeck U, Rabkin E et al. Evidence for increased collagenolysis by interstitial collagenases 1 and -3 in vulnerable human atheromatous plaques. Circulation 99(19), 2503-2509 (1999).
66. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Invest. 94, 2493-2503 (1994).
67. Morishige K, Shimokawa H, Matsumoto Y et al. Overexpression of matrix metalloproteinase-9 promotes intravascular thrombus formation in porcine coronary arteries in vivo. Cardiovasc. Res. 57(2), 572-585 (2003).
68. Lipinski Mj, Fuster V, Fisher Ea, Fayad Za. Technology insight: targeting of biological molecules for evaluation of high-risk atherosclerotic plaques with magnetic resonance imaging. Nat. Clin. Pract. Cardiovasc. Med. 1, 48-55 (2004).
69. Chen W, Cormode DP, Fayad ZA, Mulder WJM. Nanoparticles as magnetic resonance imaging contrast agents for vascular and cardiac diseases. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 3(2), 146-161 (2011).
70. Kelly KA, Allport JR, Tsourkas A, Shinde-Patil VR, Josephson L, Weissleder R. Detection of vascular adhesion molecule-1 expression using a novel multimodal nanoparticle. Circ. Res. 96(3), 327-336 (2005).
71. Nahrendorf M, Jaffer FA, Kelly KA et al. Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation 114(14), 1504-1511 (2006).
72. Kang HW, Torres D, Wald L, Weissleder R, Bogdanov AA. Targeted imaging of human endothelial-specifmarker in a model of adoptive cell transfer. Lab. Invest. 86(6), 599-609 (2006).
73. Woollard KJ, Chin-Dusting J. Therapeutic targeting of P-selectin in atherosclerosis. Inflamm. Allergy Drug Targets 6(1), 69-74 (2007).
74. Jacobin-Valat M-J, Deramchia K, Mornet S et al. MRI of inducible P-selectin expression in human activated platelets involved in the early stages of atherosclerosis. NMR Biomed. 24(4), 413-424 (2011).
75. Perez-Balderas F, Davis BG, Vankasteren SI. New biodegradable multimeric MPIO contrast agent shows rapid in vitro and in vivo degradation and high sensitivity contrast. Proc. Intl. Soc. Mag. Reson. Med. 19, 1689 (2011).
76. McAteer MA, Schneider JE, Ali ZA et al. Magnetic resonance imaging of endothelial adhesion molecules in mouse atherosclerosis using dual-targeted microparticles of iron oxide. Arterioscler. Thromb. Vasc. Biol. 28(1), 77-83 (2008).
77. McAteer MA, Akhtar AM, Von Zur Muhlen C, Choudhury RP. An approach to molecular imaging of atherosclerosis, thrombosis, and vascular inflammation using microparticles of iron oxide. Atherosclerosis 209(1), 18-27 (2010).
78. Alsaid H, De Souza G, Bourdillon M-C et al. Biomimetic MRI contrast agent for imaging of inflammation in atherosclerotic plaque of apoE-/- mice: a pilot study. Invest. Radiol. 44(3), 151-158. (2009).
79. Smith B, Heverhagen J, Knopp M et al. Localization to atherosclerotic plaque and biodistribution of biochemically derivatized superparamagnetic iron oxide nanoparticles (SPIONs) contrast particles for magnetic resonance imaging (MRI). Biomed. Microdevices 9(5), 719-727 (2007).
80. Sosnovik DE, Schellenberger EA, Nahrendorf M et al. Magnetic resonance imaging of cardiomyocyte apoptosis with a novel magneto-optical nanoparticle. Magn. Reson. Med. 54(3), 718-724 (2005).
81. Kanwar JR, Mahidhara G, Kanwar RK. Antiangiogenic therapy using nanotechnological-based delivery system. Drug Discov. Today 16(5-6), 188-202 (2011).
82. Kerwin WS, O'Brien KD, Ferguson MS, Polissar N, Hatsukami TS, Yuan C. Inflammation in carotid atherosclerotic plaque: a dynamic contrast-enhanced MR imaging study. Radiology 241(2), 459-468 (2006).
83. Winter PM, Morawski AM, Caruthers SD et al. Molecular imaging of angiogenesis in early-stage atherosclerosis with avb3-integrin-targeted nanoparticles. Circulation 108(18), 2270-2274 (2003).
84. Winter PM, Neubauer AM, Caruthers SD et al. Endothelial avb3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 26(9), 2103-2109 (2006).
85. Winter PM, Caruthers SD, Zhang H, Williams TA, Wickline SA, Lanza GM. Antiangiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosis. JACC Cardiovasc. Imaging 1(5), 624-634 (2008).
86. Von Zur Muhlen C, Von Elverfeldt D, Moeller JA et al. Magnetic resonance imaging contrast agent targeted toward activated platelets allows in vivo detection of thrombosis and monitoring of thrombolysis. Circulation 118(3), 258-267 (2008).
87. Von Zur Muhlen C, Peter K, Ali ZA et al. Visualization of activated platelets by targeted magnetic resonance imaging utilizing conformation-specific antibodies against glycoprotein IIb/IIIa. J. Vasc. Res. 46(1), 6-14 (2009).
88. Wickline SA, Neubauer AM, Winter PM, Caruthers SD, Lanza GM. Molecular imaging and therapy of atherosclerosis with targeted nanoparticles. J. Magn. Reson. Imaging 25(4), 667-680 (2007).
89. Flacke S, Fischer S, Scott MJ et al. Novel MRI contrast agent for molecular imaging of fibrin. Circulation 104(11), 1280-1285 (2001).
90. Yu X, Song S-K, Chen J et al. High-resolution MRI characterization of human thrombus using a novel fibrin-targeted paramagnetic nanoparticle contrast agent. Magn. Reson. Med. 44(6), 867-872 (2000).
91. Pan D, Senpan A, Caruthers SD et al. Sensitive and efficient detection of thrombus with fibrin-specific manganese nanocolloids. Chem. Commun. (22), 3234-3236 (2009).
92. Pan D, Caruthers SD, Hu G et al. Ligand-directed nanobialys as theranostic agent for drug delivery and manganese-based magnetic resonance imaging of vascular targets. J. Am. Chem. Soc. 130(29), 9186-9187 (2008).
93. Senpan A, Caruthers SD, Rhee I et al. Conquering the dark side: colloidal iron oxide nanoparticles. ACS Nano 3(12), 3917-3926 (2009).
94. McCarthy JR, Patel P, Botnaru I, Haghayeghi P, Weissleder R, Jaffer FA. Multimodal nanoagents for the detection of intravascular thrombi. Bioconj. Chem. 20(6), 1251-1255 (2009).